ENTRY       D09939                      Drug
NAME        Olaratumab (USAN/INN);
            Olaratumab (genetical recombination) (JAN);
            Lartruvo (TN)
FORMULA     C6554H10076N1736O2048S40
EXACT_MASS  147148.6495
MOL_WEIGHT  147239.1336
SEQUENCE    (Heavy chain)
            QLQLQESGPG LVKPSETLSL TCTVSGGSIN SSSYYWGWLR QSPGKGLEWI GSFFYTGSTY
            YNPSLRSRLT ISVDTSKNQF SLMLSSVTAA DTAVYYCARQ STYYYGSGNY YGWFDRWDQG
            TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF PEPVTVSWNS GALTSGVHTF
            PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP
            APELLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK
            PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT
            LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL
            TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK
            (Light chain)
            EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD ASNRATGIPA
            RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RSNWPPAFGQ GTKVEIKRTV AAPSVFIFPP
            SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
            LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
            (Disulfide bridge: H22-H97, H154-H210, H271-H331, H377-H435, H236-H'236, H239-H'239, L23-L88, L134-L194, H230-L214)
  TYPE      Peptide
REMARK      ATC code: L01FX10
EFFICACY    Antineoplastic, Anti-platelet-derived growth factor (PDGF) receptor alpha antibody
  DISEASE   Soft tissue sarcoma [DS:H02427]
  TYPE      Monoclonal antibody
COMMENT     Treatment of soft tissue sarcoma
TARGET      PDGFRA [HSA:5156] [KO:K04363]
  PATHWAY   hsa04010(5156)  MAPK signaling pathway
            hsa05200(5156)  Pathways in cancer
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
                L01FX Other monoclonal antibodies and antibody drug conjugates
                 L01FX10 Olaratumab
                  D09939  Olaratumab (USAN/INN)
            USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Olaratumab
                D09939  Olaratumab (USAN/INN)
            Target-based classification of drugs [BR:br08310]
             Protein kinases
              Receptor tyrosine kinases (RTK)
               PDGFR family
                PDGFRA
                 D09939  Olaratumab (USAN/INN)
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D09939
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D09939
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D09939
DBLINKS     CAS: 1024603-93-7
            PubChem: 124490624
///
